Side effects of calciferol
Pro Research Analysisby 
Searched over 200M research papers
Side Effects of Calciferol: A Comprehensive Review
Hypercalcemia and Hyperphosphatemia in Hemodialysis Patients
Calciferol, commonly known as vitamin D, is frequently used in various forms to manage conditions such as secondary hyperparathyroidism in hemodialysis patients. One of the significant side effects observed with calciferol treatment is hypercalcemia, an elevated level of calcium in the blood. Studies comparing oral and intravenous administration of doxercalciferol (1alpha-hydroxyvitamin D2) in hemodialysis patients have shown that hypercalcemia is less frequent with intravenous administration. Specifically, the prevalence of serum calcium levels greater than 11.2 mg/dL was significantly lower during intravenous treatment (0.86%) compared to oral treatment (3.62%) .
Additionally, serum phosphorus levels tend to increase during calciferol treatment. However, the increments in serum phosphorus levels were more pronounced during oral treatment compared to intravenous treatment, suggesting that intravenous administration may be more advantageous for patients prone to hyperphosphatemia .
Effects on Rheumatoid Arthritis Patients
In a double-blind clinical trial involving patients with rheumatoid arthritis, high doses of calciferol (100,000 IU per day) were administered for one year. While the study primarily focused on the therapeutic benefits, it also highlighted some side effects. Although the trial reported significant improvements in clinical symptoms and a reduction in the consumption of analgesics and anti-inflammatory medications, it did not explicitly mention adverse effects. This suggests that while high doses of calciferol can be beneficial, the potential side effects were either minimal or not the primary focus of the study .
Cholecalciferol Supplementation in Hemodialysis Patients
A randomized controlled trial examined the effects of cholecalciferol supplementation in hemodialysis patients with low levels of 25-hydroxyvitamin D. The study found that patients receiving cholecalciferol had significantly higher levels of 25(OH)D and 1,25-dihydroxyvitamin D without a corresponding increase in serum calcium or phosphorus levels. This indicates that cholecalciferol supplementation did not lead to hypercalcemia or hyperphosphatemia in this patient population .
Conclusion
In summary, the side effects of calciferol, particularly hypercalcemia and hyperphosphatemia, are significant considerations in its administration, especially in hemodialysis patients. Intravenous administration of doxercalciferol appears to mitigate these risks compared to oral administration. High doses of calciferol in rheumatoid arthritis patients showed therapeutic benefits with minimal reported side effects. Cholecalciferol supplementation in hemodialysis patients effectively increased vitamin D levels without causing hypercalcemia or hyperphosphatemia. These findings underscore the importance of monitoring and choosing the appropriate form and dosage of calciferol to minimize adverse effects.
Sources and full results
Most relevant research papers on this topic